I replied to your post"let's be honest with ourselve's" and found it to be a masterpiece that defines being a realist investor in these stocks. the following was posted three years ago on the INO MB and it tokk until just the last month for this stock to really take off. Read what was in the pipeline three years ago and you'll get another perspective on how much more waiting we "may" have with our beloved ONCS:
As discussed in my previous article, Minimizing Risk When Investing In Biopharmas, one of the key criteria when considering to invest in a biopharma is to take a look at the staff that comprises it. Inovio's staff management is composed of strong scientific minds, with a vast history of vaccine development and discovery, and many with ties to big pharmaceutical corporations.
CEO Joseph Kim is an Ex-Merck (MRK) employee who worked on the development of HEP A/B, and HIV vaccine R&D.
David B. Weiner, PhD and Chairman is known as the "Father of DNA vaccines" and is a member of the Dept. of Pathology & laboratory Medicine, U of PA.
Philip Greenberg, MD is an expert in T-Cell Immunology and head of the Immunology Program, Fred Hutchinson Cancer Research Center
Adel Mahmoud, PhD is a professor at Princeton University and a former President of Merck Vaccines responsible for Gardasil, Zostavax, Proquad, and Rotateq.
Anthony W. Ford-Hutchinson, PhD is also a former Senior VP of Merck vaccine R&D, and oversaw the development of Singulair, Januvia, Gardasill, Zostavax, Proquad, and Rotateq.
Stanley A. Plotkin, MD developed the Rubella and Rabies vaccine, and oversaw the Sanofi (SNY) flu vaccine.
Simon X. Benito is a former Senior VP of Merck Vaccine division.
Pipeline and Funding:
With a large pipeline, most of which have passed phase I clinical trials showing a best-in-class immune response, many important validating clinical milestones are expected very shortly over the next quarters, most within the first half of (to be continued)